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ABSTRACT  
The current studies was design and evaluate biodegradable PLGA microspheres for sustained or extended release, with primary goal of 
avoiding combination of oral therapy for the treatment of schizophrenia. PLGA copolymers 75:25 was used to prepare four micr osphere 
formulations of anti-psychotic drug Olanzapine. The microspheres were characterized by in-vitro dissolution and other physio-chemical 
methods. A simulation of multiple dosing at weekly or 15-day regimen revealed pulsatile behavior for all formulations with steady state may be 
achieved by the second dose. Overall, the in-vitro study of Formulations 001, 002, 003, or 004 will eliminate the need for combination oral 
therapy and reduce time to achieve steady state, with a smaller washout period upon duration of therapy. Results of this study prove the 
suitability of using PLGA 75:25 copolymers of different composition and molecular weight to produce sustained or extended rel ease 
formulations that can enhance pharmacological effectiveness for anti-psychotic intra-muscular administration of Olanzapine. 
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INTRODUCTION 
Antipsychotic agents involve a variety of compounds that are 
useful in the treatment of psychosis including schizophrenia. 
Antipsychotics were previously known as neuroleptics as 
these agents have ability to reduce the response to 
emotional and physical stimulation in disturbed or psychotic 
patients without any effect on consciousness.(1) 
The term psychosis means mental disorders indicated by 
symptoms like reduced and fragmental ability to understand 
information and reach to logical conclusion, catatonic or 
disorganized behavior, hallucination, delusion, excitement or 
violence.(2)  
Lifelong psychiatric disorder may be characterized as 
schizophrenia which is primarily associated with delusional, 
illogical and paranoid thoughts. Schizophrenia normally may 
have its onset in early adulthood with remission and 
exacerbations may appear throughout the life. It is estimated 
that about 1% population of world or India is affected by 
schizophrenia.(3) Symptoms of schizophrenia start with 
highly diverse set of clinical conditions in late adolescence or 
early adulthood. Schizophrenic symptoms are dividend in 
positive and negative sign or symptoms. Positive signs are 
the first to attract attention to the disorder; these include 
auditory hallucination normally where patients thought are 
perceived to be receiving from others or some sources like 
radio or cell phones. Disorganized speech, repetitive 
behavior delusions are the other positive sign in 
schizophrenia. Negative sign or symptoms are less seen but 
more sustainable and disturbing. These include social 
withdrawal, anhedonia, alogia, avolition, disorganized 
thought with blunted affects. Reduced cognitive functions 
like loss of memory and attention defects may also be 
there.(4) 
Microspheres have now been considered as reliable and 
effective release system which reduces dose, dosing 
frequency, and possibility of dose dumping with high patient 
compliance (5). Microspheres prepared by innate or 
artificial polymers provides sustained release, for instance  
polyesters used in microspheres, have the  benefit  of  using 
water as  a vehicle to  form  suspensions which  offers 
constant release of desired   drug.  It has been documented 
that release of a drug from microsphere is directly 
influenced with certain factors viz. physicochemical 
properties of a drug, primary burst and excipients (6). 
Injectable microsphere systems were developed in late 70’s. 
Poly (lactide) and/or poly (lactide-co-glycolide)(7-10)was 
used to encapsulate an ester of norethisteron called NET via 
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oil-in-water emulsion/solvent evaporation process. These 
microcrystals of NET were encapsulated into microspheres 
of PLA and PLGA. Since then PLGA has been the first choice 
of polymer for preparation of microspheres to encapsulate 
APIs using w/o or o/w emulsion/solvent evaporation 
technique(6-7). Poly (ε-caprolactone) is the secondly most 
accepted polymer for preparation of microspheres to 
encapsulate APIs. Moreover   PLGA, PCL and PLA, diblock 
copolymers of lactide, ethylene glycol, L-lactide and ε-
caprolactone, triblock co polymers of caprolactons, lactides 
and glycolides, have also  been  used  to  encapsulate  APIs  
via  o/w emulsion / solvent evaporation. (6) 
Biodegradation rate of the microspheres is directly linked to 
its composition which in turn affects the release profiles of 
API. For instance as PGA, PLA and PCL have hydrolytic 
degradation rate in order of PGA > PLA >> PCL. PCL have 
excellent permeability in case of steroidal drugs but it shows 
slow biodegradation, in contrast, PLA and PGA had inferior 
permeability in case of steroidal drugs but it shows 
homogenous biodegradation. It has been observed that 
microspheres of PLGA get degraded quicker and release of 
API is more rapid from the microspheres when hydrophilic 
glycolide component is increased in the system.  The 
polymer’s chirality, density of cross linking and loading of 
drugs in microspheres also influences the release profiles of 
API. Casein and chitosan microspheres shows slower release 
of API particularly when the amount of cross linking is 
increases significantly as it results in increased barrier 
density for drug diffusion, with reduction in the drug 
loading. Higher initial burst in microspheres has been 
observed when un-encapsulated drug is available in higher 
quantity on the surface of microspheres.(6) 
Olanzapine: (11-12) 
 
IUPAC Name: 2-methyl-4(-4-methyl-l-piperazinyl)-10H-
thieno-[2,3-b][l,5]-benzo-di- azepine. 
Molecular formula:          C17H20N4S 
Molecular Weight:           312.4 
Solubility: water insoluble, in moderation soluble in 
acetonitrile, soluble in organic solvents such as DMSO and 
dimethyl formamide. 
Category: Antipsychotic. 
Description: A yellow crystalline powder. 
MATERIALS AND METHODS 
Materials 
Olanzapine was obtained as a gift sample from Jubilant 
Pharmaceutcals, India, and PLGA 75:25 from Resomer 
provided by Amneal Pharmaceuticals, India. All other 
chemicals were also obtained commercially as 
Pharmaceutical grade reagents by Amneal Pharmaceuticals, 
India. 
 
Preparation of Microspheres 
Several methods for preparation of microsphere are 
reported in literature. In some cases, slight variations in 
basic methods are also reported. These variations in basic 
methods can produce numerous changes in final outcome. 
However, some of the basic techniques for microsphere 
preparation were gathered from literature survey. 
Interfacial polymerization technique is normally used for 
encapsulation of liquid. This technique involves two 
monomers one is water soluble and other is oil soluble. 
However, this process few limitations like reaction between 
active substance and reagent, toxicity produced due to 
untreated monomer, degradation resulted by monomer 
reaction and high permeability of coating and fragility of 
microsphere. 
Another method is water immiscible liquid core in which 
isocynate or some other polymers are used. Various 
modification of coacervation phase separation techniques 
are used however in present study solvent extraction 
method was used for preparation of long acting intra 
muscular microsphere. This technique is simple with high 
yielding and economic. It has been found that this method 
gives reproducible results. Equipments required in this 
technique were available in the laboratory i.e. Static mixer 
peristaltic pump, tanks of different capacity sieve of different 
pore size.  
Method of Preparation 
In the present study solvent extraction method has been 
used. A static mixture was used to reduce the globule size of 
primary emulsion prepared passing through the static mixer. 
Two separate phases one dispersing phase containing 
polymer and API in organic solvent(s) was mixed or 
homogenized with dispersion media, containing aqueous 
solution of PVA and ethyl acetate at a predefined rate. The 
primary emulsion was mixed with quenching liquid with 
lesser amount ethyl acetate in water at 6-7˚C for 4 hours 
with constant stirring. 
This process was used for slow solvent extraction from 
microspheres. The microspheres after solidification were 
passed through the sieve to remove particles of less than 25 
microns and more than 500 microns. The collected 
microspheres were lyophilized at 5˚C for 48 hours. This 
method was used for preparation of placebo microspheres, 
however for microspheres containing API; was dissolved in 
benzyl alcohol and mixed with polymer solution to achieve 
disperse phase. The microspheres were characterized as 
described in Section Characterization of Microspheres.            
Characterization of Microspheres 
Particle Size 
Particle sized measurement of prepared formulation was 
done by Bacman coulter counter. Sample was prepared by 
suspending microspheres 1mg per mL in distilled water 
along with 0.1% w/v polysorbate 80 as surfactant. Readings 
for D10, D50 and D90 were recorded for each sample. Each 
sample was run in triplicate and mean value were taken for 
study.   
Surface Morphology 
The surface morphology was examined by scanning electron 
microscopy (SEM) (Jeol JSM 17100 JEC-300 FC Auto fin 
coater) at an appropriate magnification, after 
palladium/gold coating of the microsphere sample on an 
aluminum stub. 
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Drug Content 
Olanzapine content in the microspheres was analyzed by 
HPLC method using a Column C18, Drug content (%) was 
expressed as the “weight of drug in microspheres/weight of 
microspheres × 100.” 
 
RESULTS AND DISCUSSION  
Particle Size Measurement of Microsphere 
Particle size measurement was determined with the help of 
laser diffraction method for all four formulations. Results are 
presented in Table 1, D90 of all formulations was found in 
good agreement with previous studies. Similarly, D50 values 
are also acceptable for all four formulations. 
  
Table 1 : Particle Size results of finished formulation 
Sr. No. Formulation Code 
Mean Value 
D10 
Mean Value 
D50 
Mean Value 
D90 
1 Formulation 400-PP001 49.4 89.6 148.3 
2 Formulation 400-PP002 41.8 88.7 154.0 
3 Formulation 400-PP003 46.5 86.7 158.4 
4 Formulation 400-PP004 41.5 83.9 145.9 
 
Surface Morphology of Microspheres 
The SEM images presented for microspheres were observed 
at magnification X60 and X2000. The images revealed that 
spherical shape of drug particles in developed formulation in 
comparison to microspheres where particles were found 
segregated with smooth surface without crack and pores. 
The images are shown in figure 1. 
   
 
Figure 1: image at 5.0 kV and x60 
 
Drug Content of Microsphere 
For Drug content of olanzapine in final product (long acting 
microspheres) and to determine the percent drug loading of 
olanzapine, HPLC method with UV detector was used. 
Standard solution of olanzapine was used as reference and 
peak area of standard was used to calculate the quantities of 
olanzapine in sample solution. Similar process was used 
assayed for four selected batches. Assay of all four 
formulations was found satisfactory in terms of drug 
loading. Results are mentioned in Table:2 
 
Table 2: Assay of olanzapine finished formulation 
Sr.No: Formulation Code Assay % Drug Loading 
1 Formulation 400-PP001 96.25 38.5 
2 Formulation 400-PP002 97.5 39.0 
3 Formulation 400-PP003 94.75 37.9 
4 Formulation 400-PP004 98.75 39.5 
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CONCLUSIONS 
From the present study, it is concluded that solvent 
evaporation method can be used successfully for 
preparation of microspheres. The size of the microspheres 
can be controlled well with an ideal polymer used in the 
formulations. 
Intramuscular depot forming microspheres are widely used 
for extended release under special conditions like psychosis, 
schizophrenia and related conditions where frequent dosing 
is not possible due to patient non compliance. Present work 
is done on olznzapine which is antipsychotic in action. In 
vivo release rate studies of the formulation is still due. 
However in vitro release rate study at elevated temperature 
is found to be satisfactory. If biological studies (Release rate, 
bioavailability and duration of action) are found satisfactory 
the process may be used for commercial production of 
formulation. 
Finally, it can be calculated that Olanzapine microspheres 
may be formulated using said process and parameters with 
desire sustain action. 
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